U.S. Housing Rebound
Tap into the growing strength of America's housing market. Our financial experts have carefully selected companies poised to benefit from the uptick in new home construction and sales, from leading homebuilders to essential material suppliers.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
DR Horton, Inc.
DHI
Current price
$168.11
As one of the largest homebuilders in the U.S., D.R. Horton directly benefits from a surge in new home sales through increased revenue and order backl...
As one of the largest homebuilders in the U.S., D.R. Horton directly benefits from a surge in new home sales through increased revenue and order backlogs.
Home Depot, Inc., The
HD
Current price
$407.20
The Home Depot sees increased sales from both professional contractors building new homes and from new homeowners purchasing goods for their propertie...
The Home Depot sees increased sales from both professional contractors building new homes and from new homeowners purchasing goods for their properties.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
The recent surge in new home sales signals renewed buyer confidence in the U.S. housing market. This collection captures companies across the entire value chain that stand to benefit from this economic rebound, from builders constructing the homes to suppliers providing essential materials.
What You Need to Know
Housing is a fundamental driver of economic growth that creates ripple effects throughout many industries. When home construction increases, it boosts employment, drives demand for materials, and increases consumer spending on home-related products, benefiting multiple sectors simultaneously.
Why These Stocks
These companies were strategically selected to represent the complete housing market ecosystem. The mix includes major homebuilders with direct exposure to new construction, material suppliers who provide essential components, and manufacturers of fixtures and appliances for new homes.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+21.66%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 21.66% over the next year.
Stocks Rated Buy by Analysts
7 of 15 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 15.7% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
The Housing Boom is Just Starting
Recent data confirms a significant turnaround in new home sales after previous declines. This early-stage recovery means you could get in before the market fully prices in the housing rebound.
Catch the Ripple Effect
When housing rebounds, it doesn't just lift homebuilders. The ripples spread to material suppliers, home improvement retailers, and fixture manufacturers, creating multiple opportunities within a single trend.
Housing Leads Economic Recovery
Housing is traditionally one of the first sectors to signal economic strength. By investing in these companies now, you're positioning yourself to potentially benefit from both industry-specific growth and broader economic momentum.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Beyond The App Store: Europe's New Rules
Following regulatory pressure from the European Union, Google has revised its Play Store rules to permit alternative payment systems. This change creates a new investment opportunity in companies poised to benefit from a more open mobile app ecosystem.
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Frequently Asked Questions
Everything you need to know about the product and billing.